Dana Flanders
Stock Analyst at Guggenheim
(n/a)
# 4,407
Out of 4,829 analysts
9
Total ratings
n/a
Success rate
-27.29%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dana Flanders
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VALN Valneva SE | Maintains: Buy | $17 → $15 | $6.45 | +132.56% | 1 | Mar 24, 2025 | |
| SCYX SCYNEXIS | Initiates: Buy | $25 | $0.97 | +2,481.84% | 1 | Jan 22, 2021 | |
| PCRX Pacira BioSciences | Initiates: Neutral | n/a | $25.09 | - | 1 | May 27, 2020 | |
| HRTX Heron Therapeutics | Initiates: Buy | $24 | $2.05 | +1,070.73% | 1 | May 27, 2020 | |
| COLL Collegium Pharmaceutical | Initiates: Neutral | n/a | $29.56 | - | 1 | May 27, 2020 | |
| LGND Ligand Pharmaceuticals | Initiates: Neutral | n/a | $106.38 | - | 2 | Mar 10, 2020 | |
| EBS Emergent BioSolutions | Upgrades: Buy | $60 → $75 | $5.84 | +1,184.25% | 2 | Nov 2, 2018 |
Valneva SE
Mar 24, 2025
Maintains: Buy
Price Target: $17 → $15
Current: $6.45
Upside: +132.56%
SCYNEXIS
Jan 22, 2021
Initiates: Buy
Price Target: $25
Current: $0.97
Upside: +2,481.84%
Pacira BioSciences
May 27, 2020
Initiates: Neutral
Price Target: n/a
Current: $25.09
Upside: -
Heron Therapeutics
May 27, 2020
Initiates: Buy
Price Target: $24
Current: $2.05
Upside: +1,070.73%
Collegium Pharmaceutical
May 27, 2020
Initiates: Neutral
Price Target: n/a
Current: $29.56
Upside: -
Ligand Pharmaceuticals
Mar 10, 2020
Initiates: Neutral
Price Target: n/a
Current: $106.38
Upside: -
Emergent BioSolutions
Nov 2, 2018
Upgrades: Buy
Price Target: $60 → $75
Current: $5.84
Upside: +1,184.25%